Transcriptomic and Quantitative Proteomic Analysis of Transporters and Drug Metabolizing Enzymes in Freshly Isolated Human Brain Microvessels
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
We have investigated the transcriptomic and/or proteomic patterns of 71 solute carrier (SLC) and organic solute (OST) transporters, 34 ATP-binding cassette (ABC) transporters, and 51 metabolizing enzymes in human brain microvessels. We used quantitative RT-PCR and LC-MS/MS to examine isolated brain microvessels and cortex biopsies from 12 patients with epilepsia or glioma. SLC2A1/GLUT1, SLC1A3/EAAT1, and SLC1A2/EAAT2 were the main SLC proteins whereas ABCG2/BCRP, ABCB1/MDR1, ABCA2 and ABCA8 were the main ABC quantified in isolated brain microvessels; ABCG2/BCRP was 1.6-fold more expressed than ABCB1/MDR1, and ABCC4/MRP4 was 10 times less abundant than ABCB1/MDR1. CYP1B1 and CYP2U1 were the only quantifiable CYPs. Finally, GSTP1, COMT, GSTM3, GSTO1 and GSTM2 proteins were the main phase II enzymes quantified; UGTs and NATs were not detected. Our extensive investigation of gene and protein patterns of transporters and metabolizing enzymes provides new molecular information for understanding drug entry and metabolism in the human blood-brain barrier.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most efforts to combine transcriptomic and proteomic profiling have compared or validated the expression of genes via the abundance of their RNAs and proteins, including characterisation of abundance across healthy tissues45, changes due to neurological disorders46, and localised expression in neuronal processes47.”
From Decoding neuroproteomics: integrating the genome, translatome and functional anatomy (2014) · cites this paper as [46]
Citations
Cites
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Chen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/425589 · Cited by 1,675
Induction of phase I, II and III drug metabolism/transport by xenobiotics
Xu, C., Li, C. Y.-T., & Kong, A.-N. T. (2005) · Archives of Pharmacal Research · doi:10.1007/bf02977789 · Cited by 1,279
Hediger, M. A., Romero, M. F., Peng, J.-B., Rolfs, A., Takanaga, H., & Bruford, E. A. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1192-y · Cited by 985
Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors
Uchida, Y., Ohtsuki, S., Katsukura, Y., Ikeda, C., Suzuki, T., Kamiie, J., & Terasaki, T. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07208.x · Cited by 881
Self-citationBlood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
Kamiie, J., Ohtsuki, S., Iwase, R., Ohmine, K., Katsukura, Y., Yanai, K., Sekine, Y., Uchida, Y., Ito, S., & Terasaki, T. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9532-4 · Cited by 478
Self-citationTransporting therapeutics across the blood-brain barrier
Abbott, N. J., & Romero, I. A. (1996) · Molecular Medicine Today · doi:10.1016/1357-4310(96)88720-x · Cited by 447
Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2)
Lee, W., Glaeser, H., Smith, L. H., Roberts, R. L., Moeckel, G. W., Gervasini, G., Leake, B. F., & Kim, R. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411092200 · Cited by 365
Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human
Nozawa, T., Imai, K., Nezu, J.-I., Tsuji, A., & Tamai, I. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060194 · Cited by 351
Research works printed but not linked: 3
- Hagenbuch B., 2002, News Physiol. Sci., 17, 231
- Martinasevic M. K., 1998, Drug Metab. Dispos., 26, 1039
- Cornford E. M., 1992, Cancer Res., 52, 138
Cited by
Items 101–200 of 400
Bauer, M., Römermann, K., Karch, R., Wulkersdorfer, B., Stanek, J., Philippe, C., Maier‐Salamon, A., Haslacher, H., Jungbauer, C., Wadsak, W., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.362 · Cited by 67
Shi, J., Wang, X., Lyu, L., Jiang, H., & Zhu, H. (2018) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2018.03.003 · Cited by 66
Mészáros, M., Porkoláb, G., Kiss, L., Pilbat, A.-M., Kóta, Z., Kupihár, Z., Kéri, A., Galbács, G., Siklós, L., Tóth, A., et al. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.07.042 · Cited by 60
Storelli, F., Billington, S., Kumar, A. R., & Unadkat, J. D. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2035 · Cited by 57
“Consistent with our study, MRP1 abundance in BMECs is below the lower limit of quantification in all of the brain proteomic studies published so far.(18,21,34,35) ENT1 has also been associated with AD in a mouse AD model, where inhibition of adenosine transport (mediated by ENT1) improved AD-related loss of memory and…”
ResultCytochrome P450 1B1: An unexpected modulator of liver fatty acid homeostasis
Larsen, M. C., Bushkofsky, J. R., Gorman, T., Adhami, V. M., Mukhtar, H., Wang, S., Reeder, S. B., Sheibani, N., & Jefcoate, C. R. E. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.02.010 · Cited by 62
“Cyp1b1 is expressed in multi-potential mesenchymal stromal cells [5], liver stellate cells [6–7], endothelium [8–9] and microvessels of the brain [10].”
BackgroundBraun, C., Sakamoto, A., Fuchs, H., Ishiguro, N., Suzuki, S., Cui, Y., Klinder, K., Watanabe, M., Terasaki, T., & Sauer, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00449 · Cited by 62
Self-citationLi, J., & Zhu, H. (2020) · Molecules · doi:10.3390/molecules25112718 · Cited by 64
“For instance, Shi et al. used both global and targeted proteomics methods to compare the abundance of multiple clinically relevant DMEs in human livers with that in the commonly used human hepatic cell lines HepG2, Hep3B, and Huh7 [30].”
BackgroundInfluentialVerscheijden, L. F. M., Koenderink, J. B., de Wildt, S. N., & Rüssel, F. G. M. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03115-y · Cited by 59
Lipid nanoparticles for brain targeting III. Long-term stability and in vivo toxicity
Blasi, P., Schoubben, A., Traina, G., Manfroni, G., Barberini, L., Alberti, P. F., Cirotto, C., & Ricci, M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.06.037 · Cited by 59
“The identification of specific brain endothelial capillary receptors, still ongoing, furnished a set of molecular tools (e.g., small organic molecules, peptides and proteins, antibody) useful to functionalize the nanocarrier surface (Pardridge, 2011; Shawahna et al., 2011).”
BackgroundHuman Induced Pluripotent Stem Cell-Derived Brain Endothelial Cells: Current Controversies
Lu, T. M., Durán, J. G. B., Houghton, S., Rafii, S., Redmond, D., & Lis, R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.642812 · Cited by 58
Drug Transporters in the Central Nervous System
Stieger, B., & Gao, B. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0241-y · Cited by 61
“MDR1 ABCB1 Brain microcapillaries [142] Brain microcapillaries [32, 123] Brain microcapillaries: luminal [33]”
InfluentialIn Vitro Cerebrovascular Modeling in the 21st Century: Current and Prospective Technologies
Palmiotti, C. A., Prasad, S., Naik, P. U., Kaisar, M. A., Sajja, R. K., Achyuta, A. H., & Cucullo, L. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1464-6 · Cited by 62
“the quantitative proteomic analysis of transporters has been characterized this way [95].”
Appelt‐Menzel, A., Oerter, S., Mathew, S., Haferkamp, U., Hartmann, C., Jung, M., Neuhaus, W., & Pleß, O. (2020) · Current Protocols in Stem Cell Biology · doi:10.1002/cpsc.122 · Cited by 57
Goutal, S., Gerstenmayer, M., Auvity, S., Caillé, F., Mériaux, S., Buvat, I., Larrat, B., & Tournier, N. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.009 · Cited by 60
“The main ABC-transporters at the BBB are the P-glycoprotein (ABCB1) and the Breast Cancer Resistance Protein (ABCG2) [8].”
BackgroundSanchez‐Covarrubias, L., Slosky, L. M., Thompson, B. J., Zhang, Y., Laracuente, M., DeMarco, K. M., Ronaldson, P. T., & Davis, T. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088516 · Cited by 57
“lizing enzymes that are expressed intracellularly [1–5].”
Nutritional metabolism and cerebral bioenergetics in Alzheimer's disease and related dementias
Yassine, H. N., Self, W. K., Kerman, B. E., Santoni, G., Shanmugam, N. K. N., Abdullah, L. I., Golden, L. R., Fonteh, A. N., Harrington, M. G., Gräff, J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12845 · Cited by 54
“185 However, another RCT of acetyl-L-carnitine among early onset AD cases 45–60 , 62– 66”
Drug and xenobiotic biotransformation in the blood–brain barrier: a neglected issue
Agúndez, J. A. G., Jiménez-Jiménez, F. J., Alonso-Navarro, H., & GarcÃa-MartÃn, E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00335 · Cited by 52
“Nevertheless, many of the mentioned drug-metabolizing enzymes are inducible and hence, basal values should be considered as reference values, but cannot be extrapolated to all individuals and to all situations.”
BackgroundInfluentialThe Isolated Brain Microvessel: A Versatile Experimental Model of the Blood-Brain Barrier
Pardridge, W. M. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00398 · Cited by 50
Pelkonen, L., Sato, K., Reinisalo, M., Kidron, H., Tachikawa, M., Watanabe, M., Uchida, Y., Urtti, A. O., & Terasaki, T. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00782 · Cited by 59
Self-citationDynamic 3D On-Chip BBB Model Design, Development, and Applications in Neurological Diseases
Chen, X., Liu, C., Muok, L., Zeng, C., & Li, Y. (2021) · Cells · doi:10.3390/cells10113183 · Cited by 54
“The small lipophilic molecules such as the exosomes and liposomes have been investigated as the new drug vehicles for the CNS disease treatment, because of their ability to cross BBB without restrictions [31].”
BackgroundSystems Proteomics View of the Endogenous Human Claudin Protein Family
Liu, F., Koval, M. H., Ranganathan, S., Fanayan, S., Hancock, W. S., Lundberg, E. K., Beavis, R. C., Lane, L., Duek, P. D., McQuade, L. R., et al. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00769 · Cited by 52
de Lange, E., & Hammarlund‐Udenaes, M. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.76 · Cited by 51
“With regard to pharmacokinetics, biological system properties can be parameterized in terms of physiological tissue compartments (such as, for the CNS, blood, plasma, ECF, CSF, BBB cells, BCSFB cells, brain parenchymal cells, and tissue components such as membrane lipids and lysosomes), and their physiological/ bioche…”
BackgroundEng, M. E., Império, G. E., Bloise, E., & Matthews, S. G. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04432-w · Cited by 53
“MRP-1 to 6, 9 and 10 have been detected in human BECs, with MRP4 and 5 expressed at highest levels [34, 35, 94, 95].”
BackgroundZhang, M., Ye, G., Li, J., & Wang, Y. (2015) · Brain Tumor Pathology · doi:10.1007/s10014-015-0233-5 · Cited by 53
Role of nuclear receptors in the regulation of drug transporters in the brain
Chan, G. N. Y., Hoque, M. T., & Bendayan, R. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.05.004 · Cited by 56
Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases
Seo, M., & Park, T. (2021) · Biomedical Engineering Letters · doi:10.1007/s13534-021-00198-5 · Cited by 52
“The brain endothelium also expresses multiple broad-spectrum efflux pumps on their luminal surface that inhibit uptake of lipophilic molecules [8, 9].”
BackgroundCorreale, J. D., Halfón, M. J., Jack, D. L., Rubstein, A., & Villa, A. M. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103264 · Cited by 49
Chan, G. N. Y., Saldivia, V., Yang, Y., Pang, H., de Lannoy, I., & Bendayan, R. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12344 · Cited by 47
“It is important to note that although PXR is functionally expressed in in vitro and in vivo BBB models in rodents, both the transcript and protein expression of human PXR have not been previously detected in human brain capillaries (Dauchy et al. 2008; Shawahna et al. 2011).”
BackgroundMiyajima, M., Kusuhara, H., Takahashi, K., Takashima, T., Hosoya, T., Watanabe, Y., & Sugiyama, Y. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23600 · Cited by 51
Metabolite transport across the mammalian and insect brain diffusion barriers
Weiler, A., Volkenhoff, A., Hertenstein, H., & Schirmeier, S. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.02.008 · Cited by 46
Liu, L., Collier, A. C., Link, J. M., Domino, K. B., Mankoff, D. A., Eary, J. F., Spiekerman, C. F., Hsiao, P., Deo, A. K., & Unadkat, J. D. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058685 · Cited by 47
ATP-binding cassette transporter-2 (ABCA2) as a therapeutic target
Davis, W., & Tew, K. D. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.11.018 · Cited by 45
“ORP5 can also physically interact with NPC1 to facilitate the transfer of cholesterol to the endoplasmic reticulummembrane [76,77,79].”
BackgroundGazzin, S., Strazielle, N., Tiribelli, C., & Ghersi‐Egea, J. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00089 · Cited by 45
“Gene and protein expression studies conducted in human microvessels showed that CYP1B1 was the main endothelial CYP, while CYP1A1 and 2 expression levels were low or undetected (Dauchy et al., 2008; Shawahna et al., 2011).”
BackgroundYousif, S., Chaves, C., Potin, S., Margaill, I., Scherrmann, J., & Declèves, X. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07890.x · Cited by 43
“There is also evidence that the expression of BCRP in isolated human brain microvessels is higher than that of P-gp (Shawahna et al. 2011), making BCRP a key element in controlling the access of its substrates to the brain.”
BackgroundSelf-citationGhosh, C., Hossain, M., Puvenna, V., Martinez‐Gonzalez, J., Alexopolous, A., Janigro, D., & Marchi, N. (2013) · Epilepsia · doi:10.1111/epi.12318 · Cited by 44
“However, only recently was this evidence corroborated by studies conducted using an immortalized brain capillary endothelial cell line and isolated human brain microvessels (Dauchy et al., 2008, 2009; Shawahna et al., 2011).”
BackgroundResultInfluentialOhtsuki, S., Hirayama, M., Ito, S., Uchida, Y., Tachikawa, M., & Terasaki, T. (2014) · Expert Review of Proteomics · doi:10.1586/14789450.2014.893830 · Cited by 46
“For example, brain capillaries were isolated from 1 to 3 g of frozen human brain by a nylon mesh method (FIGURE 2), and recovery of capillaries was about 200–300 mg protein/g brain [12,13].”
MethodSelf-citationDoes hyperglycemia downregulate glucose transporters in the brain?
Leão, L. L., Tangen, G. G., Barca, M. L., Engedal, K., Santos, S. H. S., Machado, F. S. M., de Paula, A. M. B., & Monteiro-Júnior, R. S. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109614 · Cited by 47
Gerhartl, A., Pracser, N., Vladetic, A., Hendrikx, S., Friedl, H.-P., & Neuhaus, W. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00179-3 · Cited by 45
Ohtsuki, S., Kawakami, H., Inoue, T., Nakamura, K., Tateno, C., Katsukura, Y., Obuchi, W., Uchida, Y., Kamiie, J., Horie, T., et al. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057646 · Cited by 49
“for transporters with multiplexed multiple reaction monitoring (multiplexed MRM) as described previously (Ohtsuki et al., 2011; Shawahna et al., 2011; Uchida et al., 2011).”
MethodSelf-citationSelecting Good ‘Drug-Like’ Properties to Optimize Small Molecule Blood-Brain Barrier Penetration
Trippier, P. C. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160405112353 · Cited by 46
Kurosawa, T., Sako, D., Tega, Y., Debori, Y., Tomihara, Y., Aoyama, K., Kubo, Y., Amano, N., & Deguchi, Y. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03249-3 · Cited by 44
“This is important, because BCRP is more highly expressed than P-gp in the human BBB (43), and functional changes of BCRP at the BBB are associated with various diseases (44–46).”
BackgroundDissecting gene expression at the blood-brain barrier
Huntley, M. A., Bien-Ly, N., Daneman, R., & Watts, R. J. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00355 · Cited by 38
Toselli, F., Dodd, P. R., & Gillam, E. M. J. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1221960 · Cited by 41
“However, evidence has been found for CYP1B1 and CYP2U1 in brain microvessels at the BBB from proteomic analysis (Shawahna et al., 2011) and such studies promise to deliver a more comprehensive picture of P450 expression in the brain in coming years.”
BackgroundMethodLab-on-a-chip models of the blood–brain barrier: evolution, problems, perspectives
Deli, M. A., Porkoláb, G., Kincses, A., Mészáros, M., Szecskó, A., Kocsis, A. E., Vigh, J. P., Valkai, S., Veszelka, S., Walter, F. R., et al. (2024) · Lab on a Chip · doi:10.1039/d3lc00996c · Cited by 43
Khatri, R., Fallon, J. K., Rementer, R. J. B., Kulick, N., Lee, C. R., & Smith, P. C. (2019) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2019.106590 · Cited by 39
Rand, D., Ravid, O., Atrakchi, D., Israelov, H., Bresler, Y., Shemesh, C., Omesi, L., Zaltsman, S. L., Gosselet, F., Maskrey, T. S., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030311 · Cited by 39
“Yet, rodents BBB differ from that of humans by their permeability to P-glycoprotein substrates [86] and expression levels of tight junctions, such as claudin-5 [87] and receptors, such as Transferrin Receptor1 [88,89].”
BackgroundQuantitative and targeted proteomics-based identification and validation of drug efficacy biomarkers
Masuda, T., Mori, A., Ito, S., & Ohtsuki, S. (2020) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2020.09.006 · Cited by 38
Self-citationAndré, P., Saubaméa, B., Cochois, V., Cynthia Marie-claire, A., Cattelotte, J., Smirnova, M., Schinkel, A. H., Scherrmann, J., & Cisternino, S. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.109 · Cited by 43
“But the metabolic activities of the cytosolic monoamine oxidases and catechol-O-methyl transferase could further reduce the concentrations of these amines in tissues and their extracellular availability (GhersiEgea et al, 1988; Shawahna et al, 2011).”
BackgroundSelf-citationSynergistic induction of blood–brain barrier properties
Porkoláb, G., Mészáros, M., Szecskó, A., Vigh, J. P., Walter, F. R., de Figueiredo, R. M., Kálomista, I., Hoyk, Z., Vizsnyiczai, G., Gróf, I., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2316006121 · Cited by 40
In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery
Feng, B., Varma, M. V., Costales, C., Zhang, H., & Tremaine, L. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.922540 · Cited by 34
“One could speculate whether a very potent BBB transporter inhibitor could ever become an approved drug, due to the potential neurotoxicity that might 882 Expert Opin.”
BackgroundInfluentialBrzica, H., Abdullahi, W., Reilly, B. G., & Ronaldson, P. T. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0110-9 · Cited by 38
In Vitro Blood–Brain Barrier-Integrated Neurological Disorder Models Using a Microfluidic Device
Choi, J., Santhosh, M., & Choi, J.-W. (2019) · Micromachines · doi:10.3390/mi11010021 · Cited by 37
“There are two main transporters of the BBB, ATP‐binding cassette (ABC), which includes ABCG2/BCRP, ABCB1/MDR1, ABCA2, ABCA8, ABCC1, ABCC4, and ABCC5, and solute‐like carrier (SLC), which includes SLC7A5/LAT1, SLC2A1/GLUT1, and SLC16A1/MCT1 in a real BBB system [30].”
Al‐Majdoub, Z. M., Achour, B., Couto, N. A. S., Howard, M., Elmorsi, Y. M., Scotcher, D., Alrubia, S., El‐Khateeb, E., Vasilogianni, A., Alohali, N. A., et al. (2020) · FEBS Letters · doi:10.1002/1873-3468.13982 · Cited by 37
Ibbotson, K., Yell, J., & Ronaldson, P. T. (2017) · Fluids and Barriers of the CNS · doi:10.1186/s12987-017-0055-4 · Cited by 40
“This may be due to low basal expression of Mrp2, which may be increased in response to cellular stressors such as oxidative stress [28, 52].”
Lee, M. L., Martínez‐Lozada, Z., Krizman, E. N., & Robinson, M. B. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14135 · Cited by 38
“We examined the expression patterns of GLT-1 protein by immunofluorescence in order to confirm that the increase in GLT-1 was occurring in astrocytes specifically, as a few groups have observed GLT-1 expression in endothelial cells (Shawahna et al. 2011; Cohen-Kashi-Malina et al. 2012; Lecointre et al. 2014).”
BackgroundMethodSuhy, A., Webb, A., Papp, A. C., Geier, E. G., & Sadée, W. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.02.010 · Cited by 36
A Pharm-Ecological Perspective of Terrestrial and Aquatic Plant-Herbivore Interactions
Forbey, J. S., Dearing, M. D., Gross, E. M., Orians, C. M., Sotka, E. E., & Foley, W. J. (2013) · Journal of Chemical Ecology · doi:10.1007/s10886-013-0267-2 · Cited by 37
“…of detoxification mechanisms (Thiyagarajan and Qian, 2008; Whalen et al., 2008; Browning et al., 2010; Glenn et al., 2010; Itokawa et al., 2010; Shawahna et al., 2011; Eyckmans et al., 2012) and microbial communities (Masahira et al., 2009; Matteotti et al., 2011; Langille et al., 2012;…”
BackgroundCNS Drug Development – Lost in Translation?
Talevi, A., Bellera, C. L., Ianni, M., Gantner, M. E., Bruno‐Blanch, L. E., & Castro (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955712802762356 · Cited by 40
Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP)
Antoni, F., Bause, M., Scholler, M., Bauer, S., Stark, S., Jackson, S. M., Manolaridis, I., Locher, K. P., König, B., Buschauer, A., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112133 · Cited by 36
Chaves, C., Declèves, X., Taghi, M., Menet, M., Lacombe, J., Varlet, P., Olaciregui, N. G., Carcaboso, A. M., & Cisternino, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12050399 · Cited by 39
“the brain-to-blood transport of camptothecins like SN-38, even though MRPs are far from representing the major efflux transporters present at the BBB [43,44].”
BackgroundSelf-citationIn Vitro Models of CNS Barriers
Abbott, N. J., Dolman, D. E. M., Yusof, S. R., & Reichel, A. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_6 · Cited by 39
Glutamate Efflux at the Blood–Brain Barrier: Cellular Mechanisms and Potential Clinical Relevance
Helms, H. C. C., Uhd, N. C., & Brodin, B. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.11.004 · Cited by 36
Uchida, Y., Ohtsuki, S., & Terasaki, T. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.059055 · Cited by 34
“The peptide probes and SRM/MRM transitions reported by Agarwal et al. , Akanuma et al. , Shawahna et al. , and Uchida et al. were used (Akanuma et al., 2011; Shawahna et al., 2011; Uchida et al., 2011b; Agarwal et al., 2012).”
MethodSelf-citationLiterature review and appraisal on alternative neurotoxicity testing methods
Masjosthusmann, S., Barenys, M., El‐Gamal, M., Geerts, L., Gerosa, L., Gorreja, A., Kühne, B. A., Marchetti, N., Tigges, J., Viviani, B., et al. (2018) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2018.en-1410 · Cited by 35
Cytochrome P450 2U1, a very peculiar member of the human P450s family
Dhers, L., Ducassou, L., Boucher, J., & Mansuy, D. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2443-3 · Cited by 34
Kurosawa, T., Higuchi, K., Okura, T., Kobayashi, K., Kusuhara, H., & Deguchi, Y. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.04.032 · Cited by 33
Chaves, C., Campanelli, F., Chapy, H., Gomez‐Zepeda, D., Glacial, F., Smirnova, M., Taghi, M., Pallud, J., Perrière, N., Declèves, X., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040308 · Cited by 33
“The present results are corroborated by previous findings, where OCT1-3, PMAT and MATE1 mRNA and protein contents were also undetected or very low in Swiss mice and human isolated brain microvessels [8,10,11].”
MethodResultSelf-citationAhire, D. S., Kruger, L., Sharma, S., Mettu, V. S., Basit, A., & Prasad, B. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000449 · Cited by 33
Barriers to Drug Distribution into the Perinatal and Postnatal Brain
Ghersi‐Egea, J., Saudrais, É., & Strazielle, N. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2375-8 · Cited by 33
“In the human BBB, ABCG2 seems to be expressed at higher levels than ABCB1, while the opposite is true in the mouse (59).”
The constitutive androstane receptor and pregnane X receptor in the brain
Torres‐Vergara, P., Ho, Y. S., Espinoza, F., Nualart, F., Escudero, C., & Penny, J. I. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15055 · Cited by 32
In Silico Mechanistic Profiling to Probe Small Molecule Binding to Sulfotransferases
Martiny, V. Y., Carbonell, P., Lagorce, D., Villoutreix, B. O., Moroy, G., & Miteva, M. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073587 · Cited by 32
“Overall, most previous investigations have been prioritizing the phase I DMEs, in particular cytochromes P450 (CYPs) [9–12].”
BackgroundGartzke, D., Delzer, J., Laplanche, L., Uchida, Y., Hoshi, Y., Tachikawa, M., Terasaki, T., Sydor, J. R., & Fricker, G. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1599-5 · Cited by 33
Self-citationWang, Q., & Zuo, Z. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1513493 · Cited by 36
El‐Khateeb, E., Vasilogianni, A., Alrubia, S., Al‐Majdoub, Z. M., Couto, N. A. S., Howard, M., Barber, J., Rostami‐Hodjegan, A., & Achour, B. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107397 · Cited by 33
“In brain, the AQUA-MRM workflow was used to quantify CYPs, glutathione Stransferases (GSTs) and catechol O-methyltransferase (COMT) (Shawahna et al., 2011).”
MethodShawahna, R., Ganeshamoorthy, K., Luo, H., Scherrmann, J., Couraud, P., & Declèves, X. (2017) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-017-0412-3 · Cited by 31
“Transcriptomic and proteomic patterns of major drug transporters including influx solute carriers (SLC) and efflux ATP-binding cassette (ABC) transporters, and drugmetabolizing enzymes were reported in hCMEC/D3 cells and compared with freshly isolated human brain microvessels [1].”
BackgroundMethodSelf-citationCurrent status and advances to improving drug delivery in diffuse intrinsic pontine glioma
Arms, L., Duchatel, R. J., Jackson, E. R., Sobrinho, P. G., Dun, M. D., & Hua, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.018 · Cited by 33
Transporter Regulation in Critical Protective Barriers: Focus on Brain and Placenta
Taggi, V., Riera‐Romo, M., Piquette‐Miller, M., zu Schwabedissen, H. E. M., & Neuhoff, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071376 · Cited by 33
Zhang, Z., Uchida, Y., Hirano, S., Ando, D., Kubo, Y., Auriola, S. O. K., Akanuma, S., Hosoya, K., Urtti, A. O., Terasaki, T., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00493 · Cited by 33
Self-citationYamasaki, Y., Kobayashi, K., Okuya, F., Kajitani, N., Kazuki, K., Abe, S., Takehara, S., Ito, S., Ogata, S., Uemura, T., et al. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.081216 · Cited by 31
“As shown in Table 1, the amount of P-gp in the isolated brain capillary fraction of hMDR1-MAC mice was 2.21 fmol/mg of protein (Table 1), whereas the amounts in humans were reported to be 6.06 and 3.98 fmol/ mg of protein (Shawahna et al., 2011; Uchida et al., 2011b).”
BackgroundSelf-citationChallenges of Using In Vitro Data for Modeling P-Glycoprotein Efflux in the Blood-Brain Barrier
Sjöstedt, N., Kortejärvi, H., Kidron, H., Vellonen, K., Urtti, A. O., & Yliperttula, M. L. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1124-2 · Cited by 35
Advancing brain barriers RNA sequencing: guidelines from experimental design to publication
Francisco, D. M. F., Marchetti, L., Rodríguez‐Lorenzo, S., Frías-Anaya, E., de Figueiredo, R. M., BtRAIN Network, Heymans, M., Culot, M., Santa-Maria, A. R., Deli, M. A., et al. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00207-2 · Cited by 31
Murata, Y., Neuhoff, S., Rostami‐Hodjegan, A., Takita, H., Al‐Majdoub, Z. M., & Ogungbenro, K. (2022) · The AAPS Journal · doi:10.1208/s12248-021-00675-w · Cited by 30
Puris, E., Auriola, S. O. K., Petralla, S., Hartman, R., Gynther, M., de Lange, E. C. M., & Fricker, G. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105741 · Cited by 31
In vitro, in vivo and in silico models of drug distribution into the brain
Summerfield, S. G., & Dong, K. C. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9303-7 · Cited by 34
“Expressed within the BBB are also a range of transport systems whose role is to either supply CNS tissue with the necessary nutrients for maintenance of brain homeostasis or to act as gatekeepers and expel potentially undesirable xenobiotics [2].”
BackgroundGlia-based biomarkers and their functional role in the CNS
Jha, M. K., & Suk, K. (2013) · Expert Review of Proteomics · doi:10.1586/epr.12.70 · Cited by 30
LC–MS/MS-based quantification of efflux transporter proteins at the BBB
Gomez‐Zepeda, D., Taghi, M., Smirnova, M., Sergent, P., Liu, W., Chhuon, C., Vidal, M., Picard, M., Thioulouse, E., Broutin, I., et al. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.11.013 · Cited by 28
Self-citationJacob, A., Potin, S., Saubaméa, B., Crété, D., Scherrmann, J., Curis, E., Peyssonnaux, C., & Declèves, X. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12972 · Cited by 29
“The blood–brain barrier (BBB) is a crucial physical and biochemical barrier between brain parenchyma and the systemic circulation aiming to maintain brain homeostasis.”
BackgroundMethodSelf-citationLi, C., Cai, Y., Chen, Y., Tong, J., Li, Y., Liu, D., Wang, Y., Li, Z., Wang, Y., & Li, Q. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103262 · Cited by 27
“Absolute quantity proteomic analysis has demonstrated that the protein expression of ABCG2 is higher than that of ABCB1 in the brain microvessels of epileptic patients [4].”
Anatomy and Physiology of the Blood–Brain Barriers
Abbott, N. J. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_1 · Cited by 34
Yokel, R. A. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.05.007 · Cited by 28
Porkoláb, G., Mészáros, M., Tóth, A., Szecskó, A., Harazin, A., Szegletes, Z., Ferenc, G., Blastyák, A., Mátés, L., Rákhely, G., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070635 · Cited by 31
Knopp, R. C., Banks, W. A., & Erickson, M. A. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102648 · Cited by 29
Sifat, A. E., Vaidya, B., Villalba, H., Albekairi, T. H., & Abbruscato, T. J. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00187.2018 · Cited by 27
“Water channel/ transporters AQP4 Primarily in astrocytes (99) Increase (112) Decrease (27) Increased vasogenic edema No change (9) Decrease (66) Glucose transporters GLUT1 BBB, neurons, glia (149) Increase (83, 126, 147) Decrease (BBB) (126, 129) Decrease (30, 48, 102) Alteration of ischemic brain energy metabolism No…”
BackgroundVerscheijden, L. F. M., Litjens, C. H. C., Koenderink, J. B., Mathijssen, R. H. J., Verbeek, M. M., de Wildt, S. N., & Rüssel, F. G. M. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008786 · Cited by 29
Saleh, M. A. A., & de Lange, E. C. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010095 · Cited by 27
Colclough, N., Alluri, R. V., Tucker, J. W., Gozalpour, E., Li, D., Du, H., Li, W., Harlfinger, S., O’Neill, D. J., Sproat, G., et al. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001476 · Cited by 26
The impact of manganese on vascular endothelium
Oliveira‐Paula, G. H., Martins, A. C., Ferrer, B., Tinkov, A. A., Skalny, A. V., & Aschner, M. (2024) · Toxicological Research · doi:10.1007/s43188-024-00260-1 · Cited by 28
Ducassou, L., Jonasson, G., Dhers, L., Pietrancosta, N., Ramassamy, B., Li, Y., Loriot, M., Beaune, P. H., Bertho, G., Lombard, M., et al. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.03.014 · Cited by 27
Chaves, C., Gomez‐Zepeda, D., Auvity, S., Menet, M., Crété, D., Labat, L., Remião, F., Cisternino, S., & Declèves, X. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24697 · Cited by 27
Self-citationGrover, S., Gourie‐Devi, M., Bala, K., Sharma, S., & Kukreti, R. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283528217 · Cited by 30
Metadata
- Authors
- Shawahna, R., Uchida, Y., Declèves, X., Ohtsuki, S., Yousif, S., Dauchy, S., Jacob, A., Chassoux, F., Daumas-Duport, C., Couraud, P.-O., Terasaki, T., & Scherrmann, J.-M.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Tohoku University (JP)
- Centre Hospitalier Sainte-Anne (FR)
- Ste Anne Hospital, Paris, France
- Inserm (FR)
- Corresponding author
- Declèves, Xavier
- ORCID
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2011-07-08
- Volume
- 8
- Issue
- 4
- Pages
- 1332-1341
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2090945850
- Cited by
- 372
- References
- 48
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 23 · 2023: 19 · 2022: 27 · 2021: 26 · 2020: 31 · 2019: 20 · 2018: 30 · 2017: 29 · 2016: 29 · 2015: 35 · 2014: 27 · 2013: 32 · 2012: 24
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23790170)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- cerebral microvasculature, blood-brain barrier, solute carrier transporters, organic cation transporters, ABC transporters, drug-metabolizing enzymes, drug transporters, GLUT1, GLAST, GLT-1, MDR1/ABCB1, ABCA2, ABCA8, CYP1B1, CYP2U1, glutathione S-transferase, catechol-O-methyltransferase, glioma
- MeSH terms
- ATP Binding Cassette Transporter, Subfamily G, Member 2, Brain, Chromatography, Liquid, Glutathione Transferase, Humans, Neoplasm Proteins, ATP Binding Cassette Transporter, Subfamily B, ATP-Binding Cassette Transporters, ATP Binding Cassette Transporter, Subfamily B, Member 1, Excitatory Amino Acid Transporter 1, Excitatory Amino Acid Transporter 2, Proteomics, Glutamate Plasma Membrane Transport Proteins, Glucose Transporter Type 1, Glutathione S-Transferase pi, Tandem Mass Spectrometry, Microvessels, Transcriptome, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.